BMO Capital Raises IONS Price Target to $66
Key Points
- BMO Capital raised its price target on Ionis Pharmaceuticals to $66 from $54 on October 22, 2026, and kept an Outperform rating.
- BMO Capital's $66 price target implies 50.27% upside from Ionis Pharmaceuticals, Inc.'s ($IONS) current $43.92 share price.
- The stock traded around $43.92 recently, sitting well below its 50-day moving average of $51.48.
- Other Wall Street firms have also updated their views, with a consensus buy recommendation and a mean price target of $83.83.
Get Ionis Pharmaceuticals text alerts
We text you when insiders, Congress, analysts or big funds move on $IONS.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Ionis Pharmaceuticals, Inc. alert may contain errors. Disclosures
BMO Capital raised its price target on Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS) to $66 from $54 on October 22, 2026, while maintaining an Outperform rating on the biotechnology firm. The firm's research note highlights a positive outlook for the company's RNA-targeted medicines.
IONS
Ionis Pharmaceuticals, Inc.
BMO Capital vs. the S&P 500
Hypothetical returns from BMO Capital's disclosed trades, not real profit or advice. How we model this.
BMO Capital's Call on Ionis Pharmaceuticals
On October 22, 2026, BMO Capital issued its updated view on the biotech company, lifting its target from $54 to $66. The Outperform rating points to confidence in the firm's drug pipeline and commercial prospects.
Other Institutional Activity in Ionis Pharmaceuticals
Large investors adjusted their positions in the biotech firm ahead of the update. Two Sigma Investments, LP grew its holdings by 394,798 shares, ending with 6,252,342 shares worth about $275,478,197. Royal Bank of Canada grew its holdings by 2,380,684 shares, ending with 6,182,479 shares worth about $272,400,033.
Ionis Pharmaceuticals, Inc. Stock Up 2.3%
Ionis Pharmaceuticals shares closed at $44.06 on October 22, 2026, and recently traded around $43.92. The stock sits below its 50-day moving average of $51.48 and its 200-day moving average of $68.43. The 52-week range spans from a low of $42.08 to a high of $86.74.
$IONS price target
Ionis Pharmaceuticals, Inc. daily closes and this analyst's $66 target. Not advice.
Recent Earnings
Ionis reported $874,092,992 in trailing twelve-month revenue alongside a trailing EPS of -$3.48. The company posts a net margin of -64.7% and a return on equity of -105.5%. The next earnings update is scheduled for November 4, 2026.
Insider Buying and Selling at Ionis Pharmaceuticals, Inc.
Company insiders have made several trades in recent months. Director Michael Reuben Hayden bought 20,000 shares on July 31, 2026, valued at $1,058,700. Later, on October 16, 2026, EVP and Chief Human Resources Officer Shannon L. Devers sold 1,357 shares at $43.54 per share for a total value of $59,081.88. Officer Eric E Swayze sold 53 shares at $43.54 for $2,308 on the same day, while Officer Shannon L Devers sold another 1,357 shares at $43.54 for $59,082.
Analysts Set New Price Targets
Other firms have also updated their views on the stock recently. Guggenheim maintained a Buy rating with an $80 target on September 15, 2026. JP Morgan maintained an Overweight rating with a $70 target on September 22, 2026. HC Wainwright & Co. reiterated a Buy rating with a $100 target on September 24, 2026. UBS upgraded the stock to Buy with an $88 target on October 15, 2026. Overall, the company carries a consensus buy recommendation with a mean price target of $83.83 across 23 analyst opinions.
About Ionis Pharmaceuticals
Based in Carlsbad, California, Ionis Pharmaceuticals develops and commercializes RNA-targeted therapeutics. The company focuses on discovering treatments for severe diseases, utilizing its proprietary technology platform to advance a broad pipeline of clinical and commercial medicines.
Bottom Line
Investors will look toward the company's upcoming earnings report on November 4, 2026, for further updates on its drug pipeline and financial progress.
Related Filing Alerts
Source: BMO Capital's rating change on $IONS (Oct 22, 2026). Written by software, not financial advice. How we make alerts